EMA Head On Drug Prices, Transparency, And What Patients Really Need
This article was originally published in Scrip
To get a clearer vision of the future, sometimes you need to stand back and take stock. And this, it seems, is what Guido Rasi, newly re-appointed executive director of the European Medicines Agency, has been doing during the year since he had to relinquish his post following a ruling by the EU's civil service tribunal.
You may also be interested in...
A legislative provision under which future COVID-19 vaccines can be made available in the UK before they are approved is also being used to offer an unlicensed flu vaccine that officials say has undergone full safety, efficacy and quality tests.
With product shortages made worse by the pandemic, companies in the UK are being asked to use a new system for notifying potential supply disruptions and any plans to discontinue specific medicines.
Two new projects have begun, one on standardizing the assessment of immune responses in individuals vaccinated in clinical trials, the other to improve understanding of potential immunity in patients who have been infected with SARS-CoV-2.